Analytical Laboratory Reference · ICH Q2(R2) & Sample Traceability

Published: 2026-11-03 · Last reviewed: 2026-11-03 · Prepared by PepLab.wiki Editorial & Analytical Reference Team

How to Read a Peptide Certificate of Analysis (COA): HPLC Purity vs. Mass Assay & Sample Traceability

Direct Summary: A peptide Certificate of Analysis (COA) reports distinct analytical dimensions that cannot be substituted for one another. ICH Q2(R2) Table 1 distinguishes Impurity (Purity) from Assay (Content/Potency), while §3.1.2.2 addresses specificity/selectivity for assay, purity and impurity procedures. In commercial peptide COAs, RP-HPLC purity (%) is conventionally reported by laboratories as relative UV peak area (typically at 214 nm or 220 nm), whereas mass assay (net peptide content) quantifies the actual amount or concentration of target peptide (mg/vial or mg/mL) using the stated method. Furthermore, by analogy to general laboratory sample-accountability principles, a matching batch or lot number on a PDF does not by itself prove that an untested shipped vial matches the tested specimen or establish sterility or clinical safety.

Cite & Share Reference: Simms vs. True Peptides (19-Peptide COA Audit) → Jump to Printable COA Worksheet ↓

1. ICH Q2(R2) Analytical Distinction

Chromatographic Purity (%) vs. Mass Assay (Net Content)

The single most common error when evaluating research peptides is mistaking RP-HPLC Purity (%) for Net Peptide Content (Assay). International analytical validation guidance (ICH Q2(R2) Table 1 & §3.1.2.2 [1]) separates impurity/purity procedures from content/potency assays:

  • RP-HPLC Purity (% Peak Area — Vendor/Lab Convention): In commercial peptide testing, laboratories conventionally report chromatographic purity as the area of the main target peptide peak relative to total UV-absorbing peptide-related peaks (commonly at 214 nm or 220 nm). Because water, inorganic salts, counter-ions (trifluoroacetate / TFA, acetate), and non-UV excipients (such as mannitol) do not absorb similarly in the chromatogram, a sample can report 99.2% HPLC purity while containing only 7.4 mg of active peptide in a nominally labeled 10 mg vial.
  • Mass Assay (Net Peptide Content): Quantifies the amount or concentration of target peptide in the tested sample using the stated calibration standard and method. In general analytical chemistry, gross powder mass, net peptide content, counter-ions/salts, and residual moisture are distinct quantities and are not interchangeable. Note also whether a lab tested a lyophilized vial (mg/vial) or an already-reconstituted liquid sample reported as concentration (mg/mL; see Janoshik [4]).
  • Impact on Reconstitution Math: Dilution concentration (C = Mass / Volume) depends on actual peptide content (mg/vial), while keeping in mind that a batch or sample assay applies to the tested vial(s) and does not guarantee zero vial-to-vial fill variance in an untested vial.

2. Orthogonal Identity Verification

Molecular Weight Confirmation via LC-MS (Daltons)

RP-HPLC retention time alone is not definitive proof of molecular identity because structurally distinct peptides can co-elute under a given gradient. Orthogonal confirmation requires Electrospray Ionization Mass Spectrometry (ESI-MS / LC-MS):

  • Multiply Charged Ion Envelope (m/z): Peptides form protonated ions ([M+2H]2+, [M+3H]3+, [M+4H]4+). Deconvolution must match the theoretical molecular weight of the target sequence:
    • Retatrutide (CAS 2381089-83-2): 4731.33 Da (g/mol)
    • Tirzepatide (CAS 2023788-19-2): 4813.45 Da (g/mol)
    • Semaglutide (CAS 910463-68-2): 4113.58 Da (g/mol)
    • BPC-157 (CAS 137525-51-0): 1419.53 Da (g/mol)
  • Multi-Compound Blends (GLOW 70mg / KLOW 80mg / CagriSema): A valid blend COA must resolve and quantify each individual constituent peak (e.g., GHK-Cu + BPC-157 + TB-500), never just a single combined total.

3. Sample Traceability & Authentication Limits

Why a Matching Lot Number Alone Does Not Prove Sample Traceability

By analogy to general laboratory sample-accountability and chain-of-custody frameworks (such as the archived FDA ORA Field Science and Laboratories Manual [2]), an analytical test result applies strictly to the specific physical specimen received and logged by the testing facility. When reviewing commercial research-supplier COAs, apply three verification checks:

CHECK A · ISSUING LAB VERIFICATION

Verify the report’s unique Task ID, Verification Key, or QR link directly on the issuing laboratory’s official domain (e.g., janoshik.com or mzbiolabs.com). A static PDF hosted only on a vendor’s server is classified as Supplier-hosted PDF linked — not independently authenticated with issuing lab.

CHECK B · THREE DISTINCT DATES

Never conflate when a price was checked with when a batch was tested. Always separate: (1) Report Test Date (when the lab analyzed the sample), (2) Report Reviewed Date (when the document was inspected), and (3) Price Checked Date.

CHECK C · WHAT A CHEMICAL COA OMITS

Standard RP-HPLC and LC-MS reports measure chemical identity, chromatographic purity, and peptide content in the tested sample. Unless separate compendial USP <71> sterility and USP <85> bacterial endotoxin (LAL) procedures are performed, a chemical COA does not establish sterility or endotoxin status — and even when performed on a sample, a sampled result applies to the tested units and does not establish every unit in a batch (USP <71>, <85>, <797> [3]).

4. Worked Documented COA Audits

Side-by-Side Analytical Walkthrough of Documented Retatrutide 10mg Batch PDFs

Below is a line-by-line analytical inspection of two public supplier-hosted COA PDFs currently indexed in our Simms Research vs. True Peptides (19-Peptide COA & Catalog Comparison) and Research Supplier Comparison tables, illustrating how reported test scope and internal arithmetic should be audited.

Commercial disclosure: Paid link: PepLab may earn a commission if you purchase through supplier links below. COA PDF links open the laboratory report directly without commercial redirect tracking.
EXAMPLE A · LOT #2026-G460 (KOVERA ANALYTICAL PDF)

Simms Research — GLP-3 RT (Retatrutide) 10 mg

  • Reported Lot & Dates: Lot #2026-G460 · Test date 2026-07-16 · Reviewed 2026-11-03
  • Reported RP-HPLC Purity: 99.611% batch-average chromatographic purity across 3 tested vials.
  • Reported Mass Assay (Net Content) & Arithmetic Audit: Three individual vials are reported at 10.39 mg, 10.74 mg, and 11.19 mg. Their arithmetic mean is 10.77 mg (matching the lower table value), whereas the top summary banner states 10.68 mg net content. Audit practice: record the 3-vial range (10.39–11.19 mg) and refer the 10.68 mg vs. 10.77 mg summary discrepancy to the issuer for clarification.
  • Authentication Status: Supplier-hosted PDF linked — not independently authenticated with issuing lab.
  • Catalog Price Basis (checked 2026-11-02): $84.00 USD standard list ($8.40 per labeled mg; $75.60 USD / $7.56 per labeled mg on eligible new-customer 1st orders with 10% partner code PEPLAB10).
Paid link: PepLab may earn a commission if you purchase through this link.
EXAMPLE B · LOT #261006 (BATCH PDF)

True Peptides — TP-RT3 (Retatrutide) 10 mg

  • Reported Lot & Dates: Lot #261006 · Test date 2026-10-14 · Reviewed 2026-11-03
  • Reported Identity & Purity: Reports LC-MS molecular mass identity confirmation and 99.9% RP-HPLC chromatographic purity.
  • Mass Assay (Net Content) Scope Limit: This PDF does not report a quantitative net peptide content / mass assay (mg/vial). While it documents LC-MS identity and chromatographic peak purity (99.9%), it cannot establish actual mg/vial fill mass without a separate content assay.
  • Authentication Status: Supplier-hosted PDF linked — not independently authenticated with issuing lab.
  • Catalog Price Basis (checked 2026-11-02): $89.00 USD list ($8.90 per labeled mg; partner referral link ?ref=peplab, no separate buyer discount code confirmed).
Paid link: PepLab may earn a commission if you purchase through this link.

5. Printable 1-Page Laboratory Bench Worksheet

Peptide Vial COA & Reconstitution Verification Worksheet

Verification Field What to Record Before Reconstitution Verification & Specification Check Bench Record (Fill In)
1. Compound & CAS Registry Confirm peptide sequence name and CAS number match experimental protocol Exact CAS & sequence match to protocol Compound: ________
2. Vial Lot / Batch Match Compare physical crimp/label lot number against COA report lot number and test date Identical lot ID; test date & documented stability/retest window verified Lot #: __________
3. Issuing Lab Authentication Check Task ID / QR code directly on issuing laboratory domain (Janoshik / MZ Biolabs / Kovera) Verified on lab portal or noted as unauthenticated PDF Task/Key: ________
4. RP-HPLC Purity (%) Record chromatographic peak area percentage and wavelength (e.g., 214 nm / 220 nm) Meets predefined project/protocol purity specification Purity: ________ %
5. Mass Assay (Net Content) Record reported sample/batch assay result (mg/vial or mg/mL) or mark “Not Reported” Record sample/batch assay result (note sampling & chain-of-custody limits for untested vials) Assay: ________ mg
6. Reconstitution Volume Bacteriostatic water added (mL) → Concentration (mg/mL) → U-100 Units Verify in PepLab Calculator ___ mL → ___ mg/mL
Reviewed by: ____________ · Date: ____________ · Protocol Spec: ____________ Reference: https://peplab.wiki/guides/how-to-read-peptide-coa#worksheet

6. Primary Regulatory & Analytical Sources

References & Methodological Footnotes

  1. [1] ICH Q2(R2): International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Validation of Analytical Procedures — Q2(R2) (Adopted November 2023; Error Correction 2025). Table 1 distinguishes Impurity (Purity) from Assay (Content/Potency); Section 3.1.2.2 addresses specificity/selectivity for assay, purity and impurity procedures. Official ICH PDF (2025 Corrected) ↗
  2. [2] FDA ORA Laboratory Manual (Archived Analogy Reference): U.S. Food and Drug Administration, Field Science and Laboratories Manual (marked archived by FDA). Cited here by analogy for general laboratory specimen accountability and chain-of-custody principles (that analytical results apply to the custody-verified specimen analyzed), not as a commercial research-supplier rule. FDA Archived Manual Page ↗
  3. [3] USP <71>, <85>, <621> & <797>: United States Pharmacopeia, General Chapter <71> Sterility Tests (USP <71> Official Preview ↗), General Chapter <85> Bacterial Endotoxins Test (USP <85> Harmonization PDF ↗), General Chapter <621> Chromatography, and General Chapter <797> Pharmaceutical Compounding — Sterile Preparations (USP <797> Reference ↗).
  4. [4] Janoshik Analytical Documentation: Can I send an already reconstituted peptide sample? Explains that reconstituted liquid peptide samples can be analyzed and reported by concentration (e.g., mg/mL). Janoshik Help Article #167 ↗

Analytical & Procurement Reference Series

Published Laboratory COA & Dilution Guides

All Guides Hub (/guides) → Simms vs. True Peptides (19-Peptide Table) →
Guide 1 · Compendial COA Verification & Printable Bench Worksheet Reviewed 2026-11-04
How to Read a Peptide Certificate of Analysis (COA): HPLC Purity (%) vs. Mass Assay & Sample Traceability
Separates RP-HPLC chromatographic peak-area purity (%) from quantitative net peptide content (mg/vial or mg/mL) under ICH Q2(R2) Table 1 & §3.1.2.2, orthogonal LC-MS molecular mass confirmation (Daltons), and laboratory sample chain-of-custody limits. Includes a printable 1-page bench worksheet.
Guide 2 · Analytical Chemistry · Gross Mass vs. Net Peptide Content Reviewed 2026-11-04
Gross Lyophilized Powder Weight vs. Net Peptide Content: Counter-Ions (TFA/Acetate), Moisture, Excipients & Solution Concentration (C = m / V)
Explains why gross lyophilized powder mass on a balance does not equal active peptide mass due to bound counter-ions (trifluoroacetate / acetate), Karl Fischer residual water, and non-volatile excipients—why no universal correction factor exists across batches—and why solution concentration (C = m / V) depends on an appropriately established quantitative content assay rather than chromatographic peak-area purity.
Guide 3 · Document-Led Supplier Report Audit · 5 Evidence States Reviewed 2026-11-04
Document-Led Peptide COA Audit: Dual-Metric (Purity + Net Content) vs. Purity-Only & Sample-Size Mismatch Certificates
Audits supplier-published batch certificates across single-compound catalog listings (Retatrutide, Tirzepatide, KPV, DSIP, Melanotan-2, Selank, SS-31, Kisspeptin-10, PT-141, Tesamorelin, BPC-157, TB-500, GHK-Cu, Ipamorelin, MOTS-c, NAD+, Epithalon), separating dual-metric PDFs, purity-only PDFs, sample-size mismatches, unextracted PDFs, and listings without a linked public COA.
Guide 4 · Multi-Analyte Chromatography & Labeled Ratio Audit Reviewed 2026-11-04
Multi-Peptide Blend COA Verification & Labeled Mass-Ratio Guide: Auditing GLOW 70mg, KLOW 80mg, Wolverine 20mg (10/10) & CJC-1295 / Ipamorelin 10mg (5/5)
Separates supplier-declared labeled mass ratios from measured constituent composition in multi-peptide vials, explains why RP-HPLC relative peak-area percentages alone do not establish mass fractions without constituent-specific calibration curves, distinguishes full-length Thymosin Beta-4 from synthetic TB-500 fragments, and documents the current COA evidence state for 4 multi-peptide blends.